Myriad Pharmaceuticals Articles
Myrexis to drop development of Azixa; 4th-qtr loss widens; names new CEO
13 September 2011
Myriad Pharma to focus on oncology portfolio, cutting staff to conserve financial resources
9 June 2010
Javelin Pharma rockets as it gets a better offer from Hospira, so ditching deal with Myriad
13 April 2010
Showing 1-3 of 3 articles
- 1
- FDA probes two deaths possibly linked to Lilly's antipsychotic Zyprexa Relprevv
- US Supreme Court says patent settlement can "sometimes" be illegal
- Negative US patent ruling for Novo Nordisk on Prandin
- Daiichi Sankyo files for Japanese approval of Prasugrel
- Osteoporosis drug bazedoxifene stops growth of breast cancer cells, even in resistant tumors
